TransThera Biosciences Lead Product TT-00420 Granted Orphan Drug Designation from FDA to Treat Cholangiocarcinoma
- Thursday, November 7, 2019, 7:15
- Environment
- Add a comment
NANJING, China, Nov. 7, 2019 /PRNewswire/ — TransThera Biosciences Co. Ltd, announced today that company received Orphan Drug Designation from US Food and Drug Administration (FDA) for TT-00420, a clinical stage investigational drug, for the treatment of cholangiocarcinoma. Dr. Frank Wu,…
About the Author
adminasapcorp has written 41555 stories on this site.